Genmab — Maj 2014
-
EHA præsentation: Ibrutinib interfererer med terapeutiske CD20-antistoffers cellemedierede antitumor-aktiviteter: implikationer for kombinationsbehandling — Mundtlig præsentation den 15. juni fra 11.00 til 11.15 dansk tid
-
de tager nok Gazyva og Arzerra sammen da det er de samme eksperter mv. der skal kigge herpå.
-
Ja fedt at de har fået en muntlig præsentation af de prækliniske data hvor de viser Arzerra er bedre end Rituan og Gazyva i Ibrutinib kombi
-
In a patient-derived DLBCL model with high (3+) CD38 expression in 80% of tumor cells by IHC, daratumumab in combination with CHOP or R-CHOP showed tumor regression and the tumors did not regrow when the treatment with daratumumab was stopped after 3 doses. The animals were tumor free at the end of the study (day 60) and showed long-term survival compared to daratumumab alone, CHOP alone or R-CHOP alone.
-
-
Ja ville være rigtig fedt hvis vi ser nye studier i DLBLC, FL, CLL, MCL eller lignende med dara i år
-
jep. Syntes MCL virker oplagt der. Ibrutinib er allerede godkendt i den indikation som er high unmet need. Kan de tilføre dara til behandlingen og gøre den langt mere effektiv må den ligge til højrebenet
-
Det jeg savner allermest lige nu er få gang i HexaBody
-
og så høre om videre steps mht. Duobody fra samtlige 5 partnere her, eller eventuelt nye
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind